Purpose: Salbutamol has been used to alleviate bronchospasm in airway disease for decades, while its potential risks have not been systematically investigated yet. The risk of any potential adverse events (AEs) in patients treated with salbutamol was assessed through systematic review and meta-analysis.
Methods: A systematic search of the literature was conducted, using EMBASE, PubMed and Cochrane library, until 3 April 2023.